AIMP2-DX2-IN-1

AIMP2-DX2-IN-1 (Compound 35) is a potent AIMP2-DX2 inhibitor with an IC50 of 0.1063 μM[1].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

IC50: 0.1063 μM (AIMP2-DX2)[1]

AIMP2-DX2-IN-1 (Compound 35) (0-1 μM, 96 h) shows inhibitory activity against A549 and H460 cells without toxicity for normal cells[1]. AIMP2-DX2-IN-1 showes very poor metabolic stability and good plasma stability in both human and mouse, and CYP inhibition need to be improved[1]. Cell Viability Assay[1] Cell Line: A549, H460 and WI-26 Concentration: 0-1 μM Incubation Time: 96 h Result: Showed inhibitory activities with EC50s of 0.690 ± 0.648 μM and 0.150 ± 0.062 μM against A549 and H460 cells, respectively. And is not active for WI-26.

[1]. Lee B, et al. Discovery of benzodioxane analogues as lead candidates of AIMP2-DX2 inhibitors. Bioorg Med Chem Lett. 2022 Jul 13;73:128889.